6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
another O
section O
of O
the O
label O
: O
* O
Bone B-OSE_Labeled_AE
Marrow I-OSE_Labeled_AE
Suppression I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
drug O
reactions O
( O
> O
= O
10 O
% O
) O
in O
patients O
receiving O
Xofigo O
were O
nausea O
, O
diarrhea O
, O
vomiting O
, O
and O
peripheral O
edema O
. O

The O
most O
common O
hematologic O
laboratory O
abnormalities O
( O
> O
= O
10 O
% O
) O
were O
anemia O
, O
lymphocytopenia O
, O
leukopenia O
, O
thrombocytopenia O
, O
and O
neutropenia O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Bayer O
HealthCare O
Pharmaceuticals O
Inc O
. O
at O
1-888-842-2937 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
the O
randomized O
clinical O
trial O
in O
patients O
with O
metastatic B-Not_AE_Candidate
castration I-Not_AE_Candidate
- I-Not_AE_Candidate
resistant I-Not_AE_Candidate
prostate I-Not_AE_Candidate
cancer I-Not_AE_Candidate
with O
bone B-Not_AE_Candidate
metastases I-Not_AE_Candidate
, O
600 O
patients O
received O
intravenous O
injections O
of O
50 O
kBq/kg O
( O
1.35 O
microcurie/kg O
) O
of O
Xofigo O
and O
best O
standard O
of O
care O
and O
301 O
patients O
received O
placebo O
and O
best O
standard O
of O
care O
once O
every O
4 O
weeks O
for O
up O
to O
6 O
injections O
. O

Prior O
to O
randomization O
, O
58 O
% O
and O
57 O
% O
of O
patients O
had O
received O
docetaxel O
in O
the O
Xofigo O
and O
placebo O
arms O
, O
respectively O
. O

The O
median O
duration O
of O
treatment O
was O
20 O
weeks O
( O
6 O
cycles O
) O
for O
Xofigo O
and O
18 O
weeks O
( O
5 O
cycles O
) O
for O
placebo O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
in O
patients O
receiving O
Xofigo O
were O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
( O
Table O
3 O
) O
. O

Grade O
3 O
and O
4 O
adverse O
events O
were O
reported O
among O
57 O
% O
of O
Xofigo-treated O
patients O
and O
63 O
% O
of O
placebo-treated O
patients O
. O

The O
most O
common O
hematologic B-OSE_Labeled_AE
laboratory I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
in O
Xofigo-treated O
patients O
( O
> O
= O
10 O
% O
) O
were O
anemia B-OSE_Labeled_AE
, O
lymphocytopenia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
and O
neutropenia B-OSE_Labeled_AE
( O
Table O
4 O
) O
. O

Treatment O
discontinuations O
due O
to O
adverse O
events O
occurred O
in O
17 O
% O
of O
patients O
who O
received O
Xofigo O
and O
21 O
% O
of O
patients O
who O
received O
placebo O
. O

The O
most O
common O
hematologic B-OSE_Labeled_AE
laboratory I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
leading O
to O
discontinuation O
for O
Xofigo O
were O
anemia B-OSE_Labeled_AE
( O
2 O
% O
) O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

Table O
3 O
shows O
adverse O
reactions O
occurring O
in O
> O
= O
2 O
% O
of O
patients O
and O
for O
which O
the O
incidence O
for O
Xofigo O
exceeds O
the O
incidence O
for O
placebo O
. O

Table O
3 O
: O
Adverse O
Reactions O
in O
the O
Randomized O
Trial O
System/Organ O
ClassPreferred O
Term O
Xofigo O
( O
n=600 O
) O
Placebo O
( O
n=301 O
) O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Pancytopenia B-OSE_Labeled_AE
2 O
1 O
0 O
0 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
36 O
2 O
35 O
2 O
Diarrhea B-OSE_Labeled_AE
25 O
2 O
15 O
2 O
Vomiting B-OSE_Labeled_AE
19 O
2 O
14 O
2 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
13 O
2 O
10 O
1 O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
impairment O
3 O
1 O
1 O
1 O
Laboratory O
Abnormalities O
Table O
4 O
shows O
hematologic B-NonOSE_AE
laboratory I-NonOSE_AE
abnormalities I-NonOSE_AE
occurring O
in O
> O
10 O
% O
of O
patients O
and O
for O
which O
the O
incidence O
for O
Xofigo O
exceeds O
the O
incidence O
for O
placebo O
. O

Table O
4 O
: O
Hematologic O
Laboratory O
Abnormalities O
Hematologic O
Laboratory O
Abnormalities O
Xofigo O
( O
n=600 O
) O
Placebo O
( O
n=301 O
) O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Anemia B-OSE_Labeled_AE
93 O
6 O
88 O
6 O
Lymphocytopenia B-OSE_Labeled_AE
72 O
20 O
53 O
7 O
Leukopenia B-OSE_Labeled_AE
35 O
3 O
10 O
< O
1 O
Thrombocytopenia B-OSE_Labeled_AE
31 O
3 O
22 O
< O
1 O
Neutropenia B-OSE_Labeled_AE
18 O
2 O
5 O
< O
1 O
Laboratory O
values O
were O
obtained O
at O
baseline O
and O
prior O
to O
each O
4-week O
cycle O
. O

As O
an O
adverse O
reaction O
, O
grade O
3-4 O
thrombocytopenia B-OSE_Labeled_AE
was O
reported O
in O
6 O
% O
of O
patients O
on O
Xofigo O
and O
in O
2 O
% O
of O
patients O
on O
placebo O
. O

Among O
patients O
who O
received O
Xofigo O
, O
the O
laboratory B-NonOSE_AE
abnormality I-NonOSE_AE
grade O
3-4 O
thrombocytopenia B-OSE_Labeled_AE
occurred O
in O
1 O
% O
of O
docetaxel O
naive O
patients O
and O
in O
4 O
% O
of O
patients O
who O
had O
received O
prior O
docetaxel O
. O

Grade O
3-4 O
neutropenia B-OSE_Labeled_AE
occurred O
in O
1 O
% O
of O
docetaxel O
naive O
patients O
and O
in O
3 O
% O
of O
patients O
who O
have O
received O
prior O
docetaxel O
. O

Fluid O
Status O
Dehydration B-OSE_Labeled_AE
occurred O
in O
3 O
% O
of O
patients O
on O
Xofigo O
and O
1 O
% O
of O
patients O
on O
placebo O
. O

Xofigo O
increases O
adverse O
reactions O
such O
as O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
and O
vomiting B-OSE_Labeled_AE
which O
may O
result O
in O
dehydration B-NonOSE_AE
. O

Monitor O
patients O
' O
oral O
intake O
and O
fluid O
status O
carefully O
and O
promptly O
treat O
patients O
who O
display O
signs O
or O
symptoms O
of O
dehydration B-NonOSE_AE
or O
hypovolemia B-NonOSE_AE
. O

Injection B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Erythema B-OSE_Labeled_AE
, O
pain O
, O
and O
edema O
at I-OSE_Labeled_AE
the I-OSE_Labeled_AE
injection I-OSE_Labeled_AE
site I-OSE_Labeled_AE
were O
reported O
in O
1 O
% O
of O
patients O
on O
Xofigo O
. O

Secondary O
Malignant O
Neoplasms O
Xofigo O
contributes O
to O
a O
patient O
's O
overall O
long-term O
cumulative O
radiation O
exposure O
. O

Long-term O
cumulative O
radiation O
exposure O
may O
be O
associated O
with O
an O
increased B-OSE_Labeled_AE
risk I-OSE_Labeled_AE
of I-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
and O
hereditary B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
. O

Due O
to O
its O
mechanism O
of O
action O
and O
neoplastic B-NonOSE_AE
changes I-NonOSE_AE
, O
including O
osteosarcomas B-NonOSE_AE
, O
in O
rats O
following O
administration O
of O
radium-223 O
dichloride O
, O
Xofigo O
may O
increase O
the O
risk O
of O
osteosarcoma B-OSE_Labeled_AE
or O
other O
secondary B-OSE_Labeled_AE
malignant I-OSE_Labeled_AE
neoplasms I-OSE_Labeled_AE
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

However O
, O
the O
overall O
incidence O
of O
new O
malignancies B-NonOSE_AE
in O
the O
randomized O
trial O
was O
lower O
on O
the O
Xofigo O
arm O
compared O
to O
placebo O
( O
< O
1 O
% O
vs O
. O
2 O
% O
; O
respectively O
) O
, O
but O
the O
expected O
latency O
period O
for O
the O
development O
of O
secondary B-NonOSE_AE
malignancies I-NonOSE_AE
exceeds O
the O
duration O
of O
follow O
up O
for O
patients O
on O
the O
trial O
. O

Subsequent O
Treatment O
with O
Cytotoxic O
Chemotherapy O
In O
the O
randomized O
clinical O
trial O
, O
16 O
% O
patients O
in O
the O
Xofigo O
group O
and O
18 O
% O
patients O
in O
the O
placebo O
group O
received O
cytotoxic B-NonOSE_AE
chemotherapy I-NonOSE_AE
after O
completion O
of O
study O
treatments O
. O

Adequate O
safety O
monitoring O
and O
laboratory O
testing O
was O
not O
performed O
to O
assess O
how O
patients O
treated O
with O
Xofigo O
will O
tolerate O
subsequent O
cytotoxic B-NonOSE_AE
chemotherapy I-NonOSE_AE
. O

